TheraRadar
← Back
Data updated: Jun 28, 2026

SUNNY

Generics

SUNNY is a generic drug manufacturer focused on Oncology, Gastroenterology, Immunology.

2018
Since
6
Drugs
-
Trials
0
New Drugs (2yr)
Modality:

SUNNY's Key Drugs

SUNNY's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

SUNNY's Recent FDA Approvals

New NDA/BLA approvals for SUNNY over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

SUNNY's Therapeutic Areas

SUNNY's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Gastroenterology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 29%
2 drugs
Gastroenterology 29%
2 drugs
Immunology 14%
1 drugs
Respiratory 14%
1 drugs
Infectious Disease 14%
1 drugs

SUNNY Pipeline Snapshot

Active clinical trials for SUNNY across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Oncology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling